Repligen vs Sotera Health
Sotera Health is the larger business, with $1.16bn of revenue in fiscal 2025 against $738m for Repligen (1.6 times as much). Repligen grew faster (16.4% against 5.7%). Sotera Health kept more of each dollar of sales as profit: a net margin of 6.7% against 6.6%. Repligen carries less debt relative to equity (25.7% against 358.0%).
| Latest fiscal year | RepligenRGEN, 2025 | Sotera HealthSHC, 2025 |
|---|---|---|
| Revenue | $738m | $1.16bn |
| Revenue growth | 16.4% | 5.7% |
| Net income | $48.9m | $77.9m |
| Operating margin | 7.5% | — |
| Net margin | 6.6% | 6.7% |
| Return on equity | 2.4% | 15.4% |
| Free cash flow | $93.9m | $149m |
| Cash | $566m | $345m |
| Total debt | $542m | $2.17bn |
| Debt to equity | 25.7% | 358.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | $0 | — |
| Employees | 2,000 | 3,000 |
| Market value | $10.13bn | $4.63bn |
| Price vs our value range | Above our value range | — |
| Moat score | 39 (Weak) | 72 (Strong) |
| Insider trades, 12 months | 0 buys, 25 sales | 0 buys, 18 sales |